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Analysis of somatic mutations 
across the kinome reveals loss-
of-function mutations in multiple 
cancer types
Runjun D. Kumar1,2 & Ron Bose1
In this study we use somatic cancer mutations to identify important functional residues within sets 
of related genes. We focus on protein kinases, a superfamily of phosphotransferases that share 
homologous sequences and structural motifs and have many connections to cancer. We develop 
several statistical tests for identifying Significantly Mutated Positions (SMPs), which are positions in an 
alignment with mutations that show signs of selection. We apply our methods to 21,917 mutations that 
map to the alignment of human kinases and identify 23 SMPs. SMPs occur throughout the alignment, 
with many in the important A-loop region, and others spread between the N and C lobes of the kinase 
domain. Since mutations are pooled across the superfamily, these positions may be important to 
many protein kinases. We select eleven mutations from these positions for functional validation. All 
eleven mutations cause a reduction or loss of function in the affected kinase. The tested mutations 
are from four genes, including two tumor suppressors (TGFBR1 and CHEK2) and two oncogenes (KDR 
and ERBB2). They also represent multiple cancer types, and include both recurrent and non-recurrent 
events. Many of these mutations warrant further investigation as potential cancer drivers.
Paired tumor-normal exome sequencing has revealed millions of somatic mutations across many thousands of 
patients1. Of these mutations, it is likely that only a small minority have a biological impact, while the majority of 
mutations are incidental to cancer development2. Identifying mutations that impact tumor biology and using this 
knowledge to guide experiments or therapeutic decision-making is a major goal.
Although the specific biologic effects of many mutations are unknown, many strategies rely on aggregating 
mutations to draw biological conclusions. For instance, mutations can be drawn from several genes to identify 
gene networks and pathways that are related to tumor growth3. Many tools also query mutations at the gene level 
to identify genes with non-random patterns of mutations that are likely related to cancer development4, 5. As the 
number of mutations increases, even regions within proteins can be assessed6, and clustered mutations can be 
detected7. Even though knowledge of specific mutations may be lacking, these approaches can guide researchers 
towards the most promising subsets of mutations for further study. However, one limitation of these approaches 
is that they operate genome-wide, often without taking into account relevant knowledge of specific gene families 
or protein types.
One particularly well-studied gene superfamily is protein kinases. These are a set of evolutationarily conserved 
phosphotransferases. There are approximately 500 protein kinase domains encoded in the human genome, spread 
between roughly 485 genes. These signaling molecules have well-known links to a variety of human diseases, 
and particularly to cancer due to their widespread functions in regulating cell behaviors8, 9. Several strategies for 
identifying biologically active mutations in protein kinases have been developed by focusing on characteristics 
specific to kinases10.
Torkamani and Schork observed that known disease-causing mutations are not randomly distributed through-
out these proteins and developed a machine-learning method for identifying these mutations11–13. When applied 
to cancer mutations, they observed that predicted functional mutations clustered in hotspots, suggesting that 
functional mutations may be shared among protein kinases14. Recent studies continue to use machine-learning 
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and kinase-specific data to improve the identification of functional mutations in kinases15, 16. KinView is a more 
recent method that allows mutations to be mapped across alignments and incorporates additional annotations. 
It is an interactive visualization program that was used to identify a loss-of-function mutation in PKCβ, a kinase 
which functions as a tumor suppressor gene17.
Another approach is to seek common effects of functional mutations. Dixit and colleagues demonstrated over 
several studies that activating protein kinase mutations shift the active-inactive equilibrium towards the active 
conformation, and that this is broadly true in many kinases18–20. Furthermore, they identified the catalytic and 
activation loops as particularly prone to gain-of-function events21, 22. Analogously, Olow et al. showed that nearly 
half of phosphorylation sites in the kinome-reactome are somatically mutated in at least some cancers23. This 
suggests that mutations with functional consequences may affect kinase substrates in addition to kinase enzymes.
It is clear that mutations occurring in one protein kinase can be used to draw inferences in another, and that 
biologically active protein kinase mutations may have some distinct characteristics which can be used to better 
identify them. However, these kinase-specific methods rely on prior structural knowledge, sets of labeled training 
mutations, or curated reaction datasets that limit generalizability beyond kinases.
In this study, we propose an alternative approach that relies only on unlabeled somatic mutations and an 
alignment of related genes or domains, which in principle is generalizable to other settings besides kinases. Rather 
than use prior knowledge of protein structure or post-translational modifications to find functional mutations, 
we first pursue the reverse task: using observed mutations and a protein kinase alignment to develop a function-
ality map of the human kinome. To do so, we design a series of statistical tests to identify aligned positions with 
non-random mutations, using our previous study of cancer genes as a starting point5. This strategy has not been 
used in prior studies of kinases or other gene families. We identify 23 homologous positions with non-random 
mutations, which is a novel finding in the field. We functionally assess eleven previously untested mutations 
across four genes by introduction into cell lines, and find that all eleven cause some reduction-of-function (ROF).
Results
Datasets. We used dGene to identify genes that have kinase domains, ultimately drawing 486 kinase domain 
sequences from 471 unique genes from Uniprot24, 25. These kinase domains were aligned using ClustalOmega 
with default settings26. The default settings are quite permissive to gaps in the alignment; this is acceptable for 
our purposes, since the analysis assumes that aligned residues have homologous functions, and a more stringent 
alignment may violate the assumption. To ensure the quality of the alignment, we compared it with results pro-
duced by alternate aligners including COBALT and MUSCLE, as well as older, manually curated alignments from 
kinase.com, and found that all were nearly identical27–29. We also manually examined the alignment to ensure 
major structural regions were aligned properly. The final alignment has 1808 positions (alignment available in 
Supplementary Table 1).
We draw 64,554 point mutations in these genes from our previous study, updated with additional mutations 
from the cBio portal (Fig. 1a, Supplementary Table 2)5, 30. 21,917 of the mutations map to the kinase domains, 
while the remainder are outside the kinase domain. Duplicate mutations from multiple sources were removed. We 
Figure 1. Study and data overview. (a) The use of mutations in the study. The process of choosing mutations 
for experimentation is in grey; the use of Significantly Mutated Positions (SMPs) is outlined. (b) Mapping of 
mutations to the protein kinase alignment. The location of 23 identified SMPs is indicated at the bottom, as well 
as the major regions of the aligned domains.
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limit scope to just point mutations (missense and silent changes), because other types of mutations like insertions 
and deletions often cannot be mapped to a single position on the alignment. 14,665 silent mutations are included 
in all in silico analyses. Positions that are systematically enriched or depleted for silent mutations may be under 
negative or positive selection, respectively, making these events a valuable source of information31, 32. Moreover, 
there is evidence that some silent mutations have important functional consequences at the protein level33, 34. The 
mutations of our dataset come from 8,674 distinct patients, although the number of patients exome sequenced 
to generate these mutations is likely 10–20% higher, since some patients will have no mutations in any protein 
kinase.
Testing Aligned Positions. Mutations were mapped onto the alignment of human kinase domains (Fig. 1b, 
Supplementary Table 2). Mutations in these genes which are outside the kinase domain are used to define the 
null distributions of test statistics, since they are produced by the same mutational processes as kinase domain 
mutations, but are unaligned. We developed a series of seven statistical tests to identify homologous positions 
with non-random mutation patterns, which can be calculated using basic approaches outlined in the Methods 
section. Importantly, these methods do not make assumptions regarding the neutrality of mutations used for the 
null distribution. The tests compare mutations at a given aligned position to unaligned mutations from outside 
the kinase domain; the goal is to identify aligned positions with mutations that appear non-random in relation to 
unaligned mutations. The tests include:
•	 Mutation Number – detects elevated numbers of mutations at an aligned position using a poisson distribu-
tion, given the observed mutation rates for residues aligned to the position.
•	 Patients – uses a chi-square statistic to detect deviations from expected patient distribution, given the number 
of mutations observed at the position.
•	 Cancer Types – uses a chi-square statistic to detect deviations from expected cancer type distribution, given 
the number of mutations observed at the position.
•	 Reference Residues – uses a chi-square statistic to detect deviations from expected distribution of mutated 
residues, given the observed residue substitution frequencies, residues aligned to the position, and the total 
number of observed mutations.
•	 Variant Residues – uses a chi-square statistic to detect deviations from expected distribution of variant resi-
dues, given the observed residue substitution frequencies, reference residues that are mutated, and the total 
number of observed mutations.
•	 Cancer Genes – detects sets of mutated genes that are enriched in predicted cancer genes, given the observed 
residue subsitution frequences, residues aligned to the position, and number of observed mutations.
•	 Gene Relatedness – detects sets of mutated genes that are more closely related than expected, given the 
observed residue substitution frequences, residues aligned to the position, and number of observed 
mutations.
Constructing a Functionality Map. Since the tests require multiple mutations and genes to be calculated, 
they were applied to the 831 positions (of 1808 total) that had mutations in at least two genes. The p-values from 
the tests were then combined using the Fisher procedure to produce a single p-value for the position35. The Fisher 
procedure (see methods for details) is commonly used to combine p-values in the context of meta-analyses36, but 
has also been used to produce consensus scores from multiple tests35. These Fisher p-values were then adjusted for 
multiple-testing to control the false discovery rate (FDR)37. We found 23 significantly mutated positions (SMP) 
with FDRs less than 0.10 (Table 1, Supplementary Table 3, Supplementary Table 4).
One possible shortcoming of the Fisher procedure is that it may prioritize positions with one extremely 
small p-value over others with multiple borderline p-values36. Therefore, we scrutinized the results to determine 
the contribution of each test to detecting SMPs (Supplementary Figure 1). If we consider a p-value of less than 
0.05 a positive result, Mutation Number detected the most SMPs (20 SMPs detected of 23 total; Supplementary 
Figure 1A). However, Cancer Genes, Gene Relatedness, Cancer Types and Patients all detected more than 5 SMPs 
each. Variant and Reference Residues contributed the least to detecting SMPs, with 4 SMPs detected by each. More 
importantly, we found that all but one SMPs were detected by multiple tests (Supplementary Figure 1B and C), 
and 11 of 23 were detected by three or more tests. In contrast, of 808 columns that were not identified as SMPs, 
only 37 were detected by two or more tests. Overall, it appears that most SMPs detected by the Fisher procedure 
have at least modest support from multiple tests.
Characterizing SMPs. SMPs are exceptional positions and differ markedly from other positions in the 
alignment. The average SMP had 377 aligned domains, versus only 75 across the entire alignment (Supplementary 
Table 5). They also had more mutations (117 versus 12) and more mutated genes (61 versus 10) than the average 
aligned position. Overall, SMPs had about twice the average number of mutations per aligned domain (0.31 
versus 0.16). This increased number of mutations reflects both a greater degree of recurrence (1.9 mutations per 
mutated gene at SMPs versus 1.25 elsewhere), as well as more genes that are mutated at SMPs (16% of aligned 
genes are mutated at SMPs, versus 13% elsewhere). SMPs were also slightly more conserved that most positions. 
SMPs had an average entropy score of 2.29, versus 1.37 for all 831 tested positions and 0.68 for all positions. 
However, entropy is markedly affected by the number of genes aligning at a given position. 18 SMPs had at least 
350 aligned genes; the mean SMP entropy of these SMPs was 2.52, while 181 non-SMPs with over 350 aligned 
genes had entropy scores of 2.86 on average. However, these are only summary statistics, and many individual 
SMPs go against these trends (Supplementary Table 5).
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When viewed against the known structure of kinase domains, these SMPs compose a map of regions that 
may be important to kinase function. In Fig. 2, we project these positions onto the EGFR kinase domain crystal 
structure. One notable group are SMPs 11–19 in Table 1 and Fig. 2; these are all very well-known activation loop 
(A-loop) residues, and many are known to host important functional mutations38. Additionally, SMP 1 (aligned 
position 145) is located in the nucleotide binding P-loop, SMPs 4 and 5 (aligned positions 246 and 254) are in the 
αC-helix, SMPs 2, 3 and 6 (aligned positions 200, 205, and 258) are in the loops either N- or C-terminal to the 
αC-helix (the β3-αC loop and the αC-β4 loop, respectively), and SMPs 9 and 10 (aligned positions 820 and 828) 
are located in or adjacent to the catalytic loop (C-loop). Well-known functional mutations at each of these posi-
tions are listed in the legend for Fig. 2 (see underlined mutations) and a recent study by Foster et al. demonstrated 
how deletion mutations in the β3-αC loop (corresponding to SMPs 2 and 3) are able to activate BRAF, EGFR, and 
ERBB2 kinases39.
Selecting Mutations for Validation. We first narrowed focus to just 14,541 unique missense mutations 
in the kinase domains (Fig. 1a). We further focus on the 42 protein kinases which we previously confirmed or 
predicted as cancer genes, reducing the candidates to 1894 mutations (genes had to have greater than even chance 
of being either an oncogene or tumor suppressor according to our previous study)5. Finally, we limited scope to 
the 23 SMPs, resulting in 218 candidate mutations.
We selected ten of these mutations for functional testing in cell culture (Table 2). We sought a mix of recurrent 
and non-recurrent events, mutations from diverse areas of the kinase domain, and a variety of cancer types. In 
particular, we tried to test mutations at several SMPs, and avoid mutations that were closely related to well studied 
functional mutations. Therefore, the mutations we selected represent a variety of novel hypotheses suggested by 
the functionality map. The mutations we selected include events in TGFBR1, CHEK2 and KDR, as well as the 
ERBB2 R868W mutation (Table 2). Five are non-recurrent, and seven are not homologuous to known functional 
mutations to our knowledge.
Our group specializes in ERBB2/HER2, and we have particular interest in mutations occuring in the terminal 
portion of the C-lobe. Since none of the mutations observed in this region occurred at an SMP, we identified addi-
tional mutations that otherwise did not meet the selection criteria. SMP 21 (position 1430 of the alignment) is one 
of the most downstream SMPs; although no mutation was observed in ERBB2 at this position, an R to C change 
occurred at this position 33 times in 23 different genes, including one observation of EGFR R958C. We therefore 





Region Fisher FDR ALK BRAF EGFR FLT3 TGFBR1 CHEK2 KDR ERBB2
1 145 P-loop 2.47E-02 G1128 G469 G724 G622 G217 G232 G846 G732
2 200 β3-αC 6.22E-02 A1148 A481 A743 A642 A230 A247 A866 A751
3 205 β3-αC 4.87E-04 L1152 L485 L747 L646 F234 I251 L870 L755
4 246 αC-helix 5.87E-02 D1163 A497 E758 A657 S241 N269 A881 E766
5 254 αC-helix 5.12E-02 I1171 L505 M766 M665 Y249 L277 L889 M774
6 258 αC-β4 2.68E-02 F1174 — V769 L668 V252 L280 I892 V777
7 717 C-lobe 2.68E-02 — — — L780 — — K997 —
8 731 C-lobe 6.55E-02 A1230 A557 C818 A792 A306 F328 S1009 C826
9 820 C-loop 5.30E-03 R1253 N580 R841 R815 K337 E351 R1032 R849
10 828 C-loop 5.87E-02 L1256 F583 L844 L818 L340 L354 L1035 L852
11 889 A-loop 3.79E-05 F1271 F595 F856 F830 L352 F369 F1047 F864
12 891 A-loop 9.46E-09 M1273 L597 L858 L832 L354 H371 L1049 L866
13 892 A-loop 6.61E-03 A1274 A598 A859 A833 A355 S372 A1050 A867
14 893 A-loop 2.83E-09 R1275 T599 K860 R834 V356 K373 R1051 R868
15 894 A-loop 2.83E-09 D1276 V600 L861 D835 R357 I374 D1052 L869
16 895 A-loop 6.39E-02 I1277 K601 L862 I836 H358 L375 I1053 L870
17 923 A-loop 9.42E-05 K1285 S605 A871 V844 — — R1061 A879
18 941 A-loop 2.47E-02 V1293 I617 I878 V852 K376 P388 L1069 I886
19 945 A-loop 8.13E-08 P1297 A621 A882 A856 A380 A392 A1073 A890
20 1134 C-lobe 2.47E-02 S1324 — T909 S883 R413 — S1100 T917
21 1430 C-lobe 5.12E-02 R1373 R704 R958 R933 R482 R474 R1150 R966
22 1467 C-lobe 2.68E-02 C1386 — M971 — — — — M979
23 1683 C-lobe 2.68E-02 — — — — — — — —
Table 1. Significantly Mutated Positions. The 23 significantly mutated positions are listed, as well as their 
aligned position, kinase region and final Fisher FDR. The corresponding residues from several well-known 
protein kinases, as well as kinases used in this study are also indicated. Kinase regions β3-αC and αC-β4 
refer to the β3-αC loop and αC-β4 loop, respectively. Positions bearing well-known functional mutations are 
underlined; positions corresponding to mutations to be tested in vitro are bolded and italicized. The complete 
listing of aligned positions and corresponding positions for all genes are in Supplementary Table 4, and 
additional summary statistics for the 23 SMPs are in Supplementary Table 5.
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Our chosen mutations also represent a variety of cancer types. They occur in a total of 73 patients with more 
than eleven distinct cancers (Supplementary Table 6). The CHEK2 K373E variant was split among many cancer 
types, but 17 patients with lung adenocarcinoma carried it. The KDR variants R1032Q and S1100F were predom-
inantly observed in 11 melanoma patients. Finally, the TGFBR1 S241L and ERBB2 R868W mutations were found 
in colorectal patients.
Experimental Results. Using a previously described retroviral transduction system40, we produced NIH 
3T3 cells stably overexpressing both mutant and wild-type proteins for each of TGFBR1, KDR and ERBB2. We 
found that we could not stably overexpress wild type CHEK2 in this setting: cells retained the selection marker, 
but stopped expressing the construct. Instead, CHEK2 experiments were performed using transient transfection 
Figure 2. Significantly Mutated Positions as they appear on the EGFR kinase crystal structure. 20 of 23 SMPs 
which have corresponding positions on the EGFR kinase crystal structure are highlighted in red. Positions 
bearing well-known functional mutations and mutations to be validated in vitro are labeled following the 
numbering of Table 1 and include: 1) BRAF G469A/V. 4) TGFBR1 S241L. 6) ERBB2 V777L, ALK F1174L/C/V/I. 
9) KDR R1032Q. 12) EGFR L858R, TGFRB1 L354P. 13) CHEK2 S372F/Y. 14) ALK R1275Q, ERBB2 R868W, 
CHEK2 K373E. 15) BRAF V600E, EGFR L861Q/R, FLT3 D835Y/V/H/E. 16) BRAF K601E, FLT3 I836M/H. 19) 
CHEK2 A392S/V. 20) KDR S1100F. 21) ERBB2 R966C. *Position is partially or fully obscured.
Gene Mutation Occurrences Region Effect on activity SMP/Aligned Column
TGFBR1 S241L 5 αC-helix ↓↓↓ 4/246
TGFBR1 L354P 1 A-loop ↓↓↓ 12/891
CHEK2 S372F 1 A-loop ↓↓↓ 13/892
CHEK2 S372Y 1 A-loop ↓↓↓ 13/892
CHEK2 K373E 48 A-loop ↓↓ 14/893
CHEK2 A392S 1 A-loop ↓ 19/945
CHEK2 A392V 2 A-loop ↓↓↓ 19/945
KDR R1032Q 6 C-loop ↓↓↓ 9/820
KDR S1100F 7 C-lobe ↓↓↓ 20/1134
ERBB2 R868W 1 A-loop ↓↓↓ 14/893
ERBB2 R966C 0† C-lobe ↓↓↓ 21/1430
Table 2. Tested mutations. Key: strongly inactivating (↓↓↓), moderately inactivating (↓↓), modestly inactivating 
(↓). †ERBB2 R966C was not directly observed in the dataset, but this amino acid substitution is common at this 
SMP in other genes (see text).
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in HEK293T cells. TGFBR1, CHEK2 and KDR constructs were tagged with FLAG. All experiments were per-
formed in duplicate or triplicate.
TGFBR1. TGFBR1 (Transforming Growth Factor Beta Receptor 1) is a receptor S/T kinase. It has well appreci-
ated functions in immune regulation as well as tissue remodeling. It is generally thought of as a tumor suppres-
sor and acts to arrest the cell cycle41, although it can also act as a pro-tumor factor in later disease progression, 
particularly by causing increased cell invasiveness, proliferation and migration42, 43. We tested two mutations in 
this gene. We found that NIH 3T3 cells overexpressing TGFBR1 S241L and L354P had reduced signaling when 
exposed to the ligand TGFβ when compared with wild type (Fig. 3a).
CHEK2. Checkpoint 2 is a cytoplasmic S/T kinase that has important functions in cell cycle control, specifi-
cally in DNA damage and repair, and is a well appreciated tumor suppressor44. We transiently transfected HEK 
293T cells with wild type CHEK2 and five variants. We confirmed previous observations that wild type CHEK2 
is constitutively activated under these conditions, as judged by phosphorylation at the autophosphorylation site 
S51645. We found that CHEK2 S372F, S372Y, and A392V all had less than 15% of the wild type phosphorylation. 
The highly recurrent mutant K373E had 45% of wild type phosphorylation, while A392S had 70% (Fig. 3b; repre-
sentative raw image Supplementary Figure 2).
KDR/VEGFR2. KDR/VEGFR2 (Vascular Endothelial Growth Factor Receptor-2) is a receptor tyrosine kinase 
(RTK). KDR is a well-established oncogene with crucial roles in angiogenesis, although there is evidence of an 
autocrine function as well46. We tested two mutations in this gene. We found that both the R1032Q and S1100F 
mutations markedly reduced function, as judged by levels of phospho-KDR and phospho-MAPK after exposure 
to the ligand VEGF (Fig. 3c).
ERBB2/HER2. ERBB2/HER2 is a member of the EGFR family of RTKs and a well known oncogene. Our lab has 
shown that point mutations in the HER2 kinase domain can trigger increased signaling and cell transformation in 
both breast40 and colorectal cell lines47. We found that HER2 R966C and R868W caused a reduction-of-function 
as judged by levels of phospho-HER2 and MAPK signaling (Fig. 3d).
Figure 3. Functional validation of mutations in TGFBR1, CHEK2, KDR/VEGFR2, and ERBB2/HER2. (a) The 
mutations TGFBR1 S241L and L354P were tested in NIH 3T3 cells in the absence and presence of ligand. (b) 
The mutations CHEK S372F/Y, K373E, and A392S/V were tested by transient transfection of HEK 293 T cells. 
(c) The mutations KDR R1032Q and S1100F were tested in NIH 3T3 cells in the absence and presence of ligand. 
(d) The mutations ERBB2 R868W and R966C were tested in NIH 3T3 cells. Western blots have been cropped 
for visualization. See methods for details.
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Analysis of Kinase Groups. Finally, using the classification scheme suggested by UniProt (Supplementary 
Table  7), we used the same procedures to identify additional SMPs within groups of related kinases 
(Supplementary Table 8). We found that groups with few members and mutations produced results that were 
highly sensitive to even single mutations; for this reason we limit the analysis to groups with more than 20 
members and 2000 kinase domain mutations, excluding the atypical and “other” kinases, since they are highly 
heterogeneous.
The largest groups (over 50 members each) yielded relatively few group-specific SMPs. Among the five largest 
groups (AGC, CAMK, CMGC, STE, TYR), only 14 SMPs could be detected, all but two of which were identified 
in the main analysis. In the STE group (which includes MAP kinases), column 269 was identified; this position 
contains numerous recurrent mutations in the group, including P124S in MAP2K1 which is common in mela-
nomas. The other group-specific SMP from these groups was column 951 in the CAMK group (which includes 
CHEK2). In contrast, the smaller tyrosine kinase-like group (TKL, 33 members, including TGFBR1 and BRAF) 
had 13 SMPs identified, 9 of which were not identified in the main analyses. These positions included columns 
887, 888 and 890, corresponding to the N-terminal portion of the A-loop. These results suggest that there may 
be additional SMPs present in smaller kinase groups, but that additional data will be required to identify them 
reliably.
Methods
Statistical Tests. We developed a panel of statistical tests which can be used to identify non-random sets 
of mutations that occur at homologous positions in human kinases. Several of these tests are adapted from our 
previous study5. In many cases, null distributions are defined empirically (via permutation). Where needed, ami-
no-acid substitution frequencies are defined by mutations that are outside kinase domains (but within genes 
bearing kinase domains) as these mutations are generated by the same mutational processes that produce the 
kinase domain mutations. Importantly, our method makes no assumptions regarding the functional status of 
these mutations; it merely assumes that mutations at some aligned positions will be enriched for functional events 
compared to unaligned mutations as a whole. That is, our method is tolerant to the fact that some non-kinase-do-
main mutations may be functional48, 49. This contrasts with prior methods which require presumably neutral 
mutations to define a null distribution, for instance by using silent mutations7. In some cases, the null distribution 
is also conditioned on the alignment and aspects of the observed mutations (for instance, most tests assume a 
fixed number of mutations).
Careful consideration was given to recurrent mutations which occur in more than one patient. These muta-
tions are often presumed to have a functional effect15, but they may also be idiosyncratic to particular genes. 
Completely excluding recurrent mutations will likely remove many biologically important mutations from the 
dataset; but completely including them will likely make the analysis sensitive to positions with even a few recur-
rent mutations. Therefore, our panel includes tests that operate at three levels, which reflect different ways of han-
dling recurrent events. Mutation-level tests (Mutation Number, Patients, and Cancer Types) include all mutations 
in the dataset, and consider recurrent events as non-redundant. Residue-level tests (Reference Residues, Variant 
Residues) treat identical amino-acid substitutions as redundant (e.g. CHEK2 K373E, which occurs 48 times in the 
dataset, is counted as a single event). Finally, gene-level tests (Cancer Genes, Gene Relatedness) treat mutations 
that occur at a single position in a gene as redundant (e.g. CHEK2 S372F and CHEK2 S372Y are treated as a single 
event). This approach should balance the value of recurrent mutations in identifying important positions against 
the risk of finding positions that are not broadly important to kinase function.
Mutation Number. In this simple test, we identify aligned positions with a higher-than-expected number of 
total mutations. All mutations are used, and the null is set using only non-kinase-domain mutations. We begin 
by defining the expected number of mutations per residue type (r) using the mutations and sequences that are 





where Er is the expected number of mutations per residue of type r, Or is the observed number of mutations 
affecting residues of type r outside of the kinase domains, and Nr is the total number of residues of type r present 
in gene sequences, but outside of their respective kinase domains. Once the expectations per residue type are set, 




where Ea is the expected number of mutations at an aligned position a; Er is the expected number of mutations per 
residue type r, and Ra,r is the number of residues aligned at a of type r. We assume that the presence of mutations 
at each gene and aligned position can be modeled with a poisson distribution, parameterized by Er for the appro-
priate residue type. It follows that the number of mutations for an entire aligned position is therefore also poisson 
distributed (since it is a sum of poisson variables), and parameterized by Ea. By comparing the observed number 
of mutations at the position with the null distribution, we generate an upper tail p-value for the test.
Patients and Cancer Types. In these tests, we identify positions with mutations that are not randomly dis-
tributed among patients and cancer types, given the number of mutations observed at the position. They 
are calculated very similarly to one another, and are described in our previous study5. Both are calculated as 
chi-square goodness-of-fit tests, although both use empirical rather than theoretical distributions. Both tests use 
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all mutations at the aligned positions. Unlike the other tests, the null distribution includes mutations in kinase 
domains, as well as mutations outside kinase domains.
Each mutation can be assigned to a patient (and cancer type), each of which has a certain mutation count 
associated with it (c). The mutation count is simply the number of times the patient (or cancer type) occurs in the 




















where Oa,c is the observed number of mutations at the aligned position from patients (cancer types) with muta-
tion count c, Ea,c is the expected number of mutations at the aligned position from patients (cancer types) with 
mutation count c, Na is the number of mutations at the position, Nc is the total number of mutations in the dataset 
from patients (cancer types) with mutation count c, and N is the total number of mutations in the dataset.
This statistic is compared to a null distribution, which is generated by calculating the statistic for random 
draws with replacement from the set of patient (cancer type) labels, holding the number of mutations fixed. The 
final output is an upper-tail p-value.
Reference Residues. This test identifies positions where mutated residues appear non-random. It is calculated 
as a chi-square goodness-of-fit test, but uses an empirical null distribution instead of a theoretical one. It is a 
residue-level test, and recurrent mutations with identical residue changes are removed. The null distribution is 
set with mutations from outside of kinase domains. We use the expected number of mutations per residue of each 
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where Oa,r is the observed number of mutations at the aligned position from residues of type r, Ea,r is the expected 
number of mutations at the aligned position at residues of type r, and Ra,r is the number of residues at the aligned 
position a of type r.
This statistic is compared to a null distribution, which is generated by calculating the statistic for random 
draws with replacement from the set amino acid types (weighted by Ea,r for each residue type), holding the num-
ber of mutations fixed. The final output is an upper-tail p-value.
Variant Residues. This test is very similar to Reference Residues, but tests for positions where the newly produced 
amino acids appear non-random. It is calculated as a chi-square goodness-of-fit test, but uses an empirical null 
distribution instead of a theoretical one. It is a residue-level test, and recurrent mutations with identical residue 
changes are removed. The null distribution is set with mutations from outside of kinase domains. We then calcu-
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where v is the type of variant residue and r is the type of reference residue. Pr,v refers to the probability that a 
mutation occurring at a residue of type r will result in a residue of type v (calculated based on the amino acid 
substitution frequencies observed outside of kinase domains), and Oa,r is the observed number of mutations at 
aligned position a with reference residues of type r.
This statistic is compared to a null distribution, which is generated by calculating the statistic for random 
draws with replacement of amino acid types (weighted by Ea,v), holding the number of mutations fixed. The final 
output is an upper-tail p-value.
Cancer Genes. This test identifies positions with mutations that tend to occur in predicted cancer genes. It is 
a gene-level test, and multiple mutations that affect a single gene at a single position are only counted once. We 
associate each gene with a score that represents how likely the gene is to be related to cancer. Cancer genes have 
smaller scores on average (for details, see “UK Score” from our previous study5).
To perform the test, we calculate the average score for the genes that are mutated at a given aligned position. 
We generate a null distribution by calculating the average score for random draws of genes (weighted by the Er 
that corresponds to each gene’s aligned residue at the given position). The result of the test is a lower-tail p-value.
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Gene Relatedness. This test identifies positions where mutated genes have kinase domains that are more closely 
relate to one another on average than expected by chance, given the mutation patterns observed outside of kinase 
domains. It is a gene-level test, and mutations that affect a single gene at a given position are only counted once. 
The distance matrix of all kinase domains in the dataset was calculated from the phylogenetic tree produced by 
ClustalOmega when it produced the alignment.
To perform the test, we calculate the average pair-wise distance for all genes that are mutated at a given aligned 
position. We generate a null distribution by calculating the average pair-wise distance for random draws of genes 
(weighted by the Er that corresponds to each gene’s aligned residue at the given position). The result of the test is 
a lower-tail p-value.
Fisher Procedure. The Fisher procedure is used to combine the individual p-values into a single consensus 
score, as was done in OncodriveFM35. The statistic is calculated:
∑−
=






where k is the number of tests being combined. The test statistic can then be used to generate an upper-tail 
p-value.
Unweighted methods like the Fisher procedure are often considered inferior to weighted methods like 
weighted Z-scores in meta-analytic problems36. However, it is important to note that there is no clear role for 
weighting in our problem, since we have no prior reason to regard one test as more reliable or powerful than any 
other, as they all rely on the same underlying dataset. Therefore an unweighted approach is most appropriate.
We did compare the Fisher method to unweighted Z-scores as discussed by Whitlock36. We found that the 
Fisher procedure and unweighted Z-scores produced highly correlated results (r = 0.903) at the 831 tested posi-
tions, and that a large majority of SMPs would be identified by either method. The Z-score method generally 
detected fewer positions at a given cut-off. For instance, if an FDR cutoff of 0.2 were applied to Z-score based 
p-values, there would be 26 positive results, 21 of which are among the 23 SMPs identified by the Fisher method 
at the cutoff of 0.1. Based on these observations, the unweighted Z-score method and the Fisher method identify 
the same positions as most likely to be significantly mutated, although the absolute p-values may differ slightly.
Missingness and Data Handling. The only variable with notable missingness was Cancer Type, which 
~20% of mutations lacked. We found that excluding these mutations from the Cancer Types test or including 
them under a “missing/other” category produced virtually identical results. The final analysis includes them as a 
separate category.
For genes with multiple isoforms, merging multiple datasets sometimes required mapping mutations to a 
common isoform. To do so, we selected the isoform that conserved the greatest number of mutations. Less than 
1% of kinase domain mutations were discarded in this process. The supplementary materials indicate when the 
mapped isoform differs from the UniProt canonical isoform. In the body of the next and figures, we refer to muta-
tions according to the canonical isoform.
Experimental Procedures and Reagents. Experiments were performed as previously described40. 
Briefly, cDNA for KDR, TGBFR1 and CHEK2 were purchased from Addgene. ERBB2 cDNA was a gift from Dr. 
Dan Leahy (Johns Hopkins University, Baltimore). Mutations were introduced using QuikChange II site-directed 
mutagenesis (Agilent). Constructs were then shuttled into the pCFG5 retroviral vector (which includes a zeocin 
resistance marker and IRES-GFP sequence) using the In-Fusion HD cloning system kit (Clonetech), and veri-
fied by full-length Sanger sequencing. For KDR, TGFBR1 and CHEK2, a c-terminal FLAG tag was introduced. 
For ERBB2, TGFBR1 and KDR, retroviral particles were produced using φNX amphotrophic packaging cells. 
NIH 3T3 cells were spin-infected with virus, and selected under 10 μg/ml zeocin for 3 weeks. Fluorescence was 
confirmed at >95% by flow cytometry or >90% by microscopy. Cells were serum starved for 6 hrs before lysate 
harvesting for each of these three genes. Cells were treated or untreated with ligand prior to harvesting in the case 
of TGBFR1 (20 min induction, 5 ng/ml) and KDR (10 min induction, 10 ng/ml). In the case of CHEK2, transient 
transfections were performed using LTX and Plus reagent from Thermo Fisher, using the manufacturers standard 
protocol in HEK 293 T cells. Cells were lysed 24 hrs after transfection. Transfection efficiency was confirmed by 
microscopy as >50% in all cases.
ERBB2/HER2 signaling was assayed using pHER2 and pMAPK levels40. TGFBR1 activity was assayed using 
pSMAD2 levels43, 50. KDR activity was assayed using pKDR51 and pMAPK levels. CHEK2 was assayed with pS516, 
which is both an autophosphorylation site and necessary for full activation of CHEK2, and has been used previ-
ously as a proxy of CHEK2 activity45, 52, 53.
NIH 3T3 cells were acquired from the American Type Culture Collection (ATCC). HEK 293 T cells were 
a gift from Dr. Akhilesh Pandey (Johns Hopkins University, Baltimore). Antibodies used include HER2 from 
Thermo-Fisher (Ab-17), phospho-HER2 (pY1248) from Millipore (06–229), p44/42 MAPK from Cell Signaling 
Technologies (CST, 137F5), phospho p44/42 MAPK from CST (20G11), FLAG from Sigma-Aldrich (F3165), 
phospho-KDR (pY1175) from CST (19A10), phospho-SMAD2 (S465/467) from CST (138D4), SMAD2 from 
CST (D43B4), phospho-CHEK2 (pS516) from CST (#2669). Ligand included VEGF165 (#8065) from CST and 
TGFβ.
Data Availability. All data generated or analysed during this study are included in this published article (and 
its Supplementary Information files).
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Discussion
In this study, we hypothesized that somatic cancer mutations could be used to identify important functional 
regions within proteins. Specifically, we focused on the superfamily of protein kinases, which are a conserved set 
of phosphotransferases that share homologous sequences and structural motifs. By mapping mutations onto the 
alignment of protein kinases and applying a panel of statistical tests, we were able to identify homologous posi-
tions that bear mutations which appear non-random. Since mutations are pooled across all superfamily members, 
these positions may be broadly important to the function of many different protein kinases.
We found 23 significantly mutated positions (SMPs) within the kinase alignment. SMPs were found through-
out the kinase domains, with the strongest enrichment in the A-loop and other major positions located in and 
around the P-loop, the αC helix, and the catalytic loop. We tested eleven distinct mutations in several genes, 
including the oncogenes ERBB2 and VEGFR2 and the tumor suppressors CHEK2 and TGFBR1. We focused 
on highly novel mutations, including many that are rare or non-recurrent, and avoided mutations with that are 
closely related to well-studied functional mutations. All eleven mutations reduced signaling through the corre-
sponding kinase. The mutations we tested were observed in 73 patients with eleven cancer types, with particularly 
large numbers of these mutations occurring in colorectal carcinomas, lung adenocarcinomas, and melanomas.
The fact that all eleven tested mutations reduced function is an important finding. It illustrates the impor-
tance of functional characterization of mutations, particularly given the diverse roles protein kinases play in can-
cer development5. In tumor suppressors, focus is often on deletions or truncations since loss-of-function events 
in tumor suppressors could act as tumor drivers. In this study, we found that both highly recurrent (CHEK2 
K373E) and rare point mutations (CHEK2 S372F/Y and A392V, TGFBR1 S241L and L354P) in tumor suppres-
sors can also cause loss- or reduction-of-function. Similarly, while it may be tempting to assume that recurrent 
point mutations in oncogenes are either neutral or gain-of-function, this work shows that these mutations can 
be loss-of-function (for instance, KDR R1032Q and S1100F). In contrast to tumor suppressors, loss-of-function 
events in oncogenes would seem to be poor candidates as tumor drivers. As it becomes more common for patients 
to have their tumors exome or genome sequenced, this knowledge will be crucial in identifying events that are 
most like to underpin their disease.
There are some important drawbacks to our approach. On a technical level, one limitation of this study is the 
focus on protein-level changes, which was necessary as DNA-level changes are not uniformly publicly available. 
However, our methods are in principle compatible with DNA-level data, and it would provide two major ben-
efits. First, applying our framework to a DNA alignment and set of nucleotide changes would allow analysis of 
non-protein regions. Second, in protein-coding regions, the use of DNA-level changes would allow us to correct 
for codon structure, potentially improving the performance of our tests.
Another caveat to this analysis is that while it provides a precise location within a gene or sets of genes to 
search for functional events, it does not identify specific mutations for testing. We addressed this problem by 
manually selecting candidate mutations from SMPs for experimentation. However, numerous methods exist that 
provide complementary functionality and could be combined with the work of this study. For instance, several 
studies have focused on identifying “hotspot” regions of genes with high densities of mutations, sometimes taking 
protein structure into account7, 54, 55. These methods can be used to identify regions within specific genes for fur-
ther study, but do not yet implicate specific residues. Functional impact predictors which use a variety of inputs 
to identify mutations that are likely to alter protein function have also been developed56, including by our own 
group57. However, impact predictors can have high rates of false-positive results, and are best used on limited 
sets of mutations with a high prevalence of functional events. Combining the methods developed in this study 
with other complementary approaches may provide an avenue for reliably identifying functional events in large 
genomic datasets.
There are other potential extensions to this study, encompassing multiple fields. We have tested only a small 
fraction of the mutations at the SMPs we identified. Direct follow up studies, particularly on ROF mutations 
in the tumor suppressors TGFBR1 and CHEK2 will be necessary before these mutations can be confirmed as 
bona fide cancer drivers. Many other mutations are found at other SMPs, and our results suggest that testing 
these mutations could be fruitful, particularly if present in genes with therapeutic implications. Our results also 
have implications for the structural understanding of kinase signaling: for instance, the ERBB2 R966C mutation 
demonstrates the importance of the C-lobe to kinase function, but the exact role this region plays is not fully 
understood.
Our methods can also be applied in other settings. Although we have focused on kinases, none of our methods 
are kinase-specific. Our analysis is equally compatible with other conserved gene or domain families of broad 
importance to cancer development, such as nuclear hormone receptors58 and G-protein coupled receptors59. Our 
methods will also become more precise as data volumes continue to increase. We found additional SMPs within 
specific groups like the TKL kinases, and more may exist in even smaller groups. New platforms that incorpo-
rate multi-sequence alignments with cancer mutation data will allow future analyses to be quickly iterated and 
focused on specific kinases17. Our methods can even be adapted to single genes, provided a sufficient density of 
observed variants.
In conclusion, we have demonstrated the use of somatic mutations to identify functional positions and muta-
tions within gene families. We developed several statistical approaches for identifying positions with non-random 
mutations, aggregating mutations across homologous positions in the human kinome to do so. We identified 
23 significantly mutated positions, and tested eleven mutations found at these positions from several genes. We 
confirmed all eleven as causing reductions in kinase function. Mutations that reduce the function of tumor sup-
pressors are particularly promising as candidate cancer drivers, though other mutations at these SMPs warrant 
study as well. Our methods are highly extensible, providing a framework for using somatic cancer data to iden-
tify functionally important regions in proteins, and eventually identifying mutations that are relevant to cancer 
development and growth.
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